Onc.AI Raises $25 Million Series A Financing Co-Led by MassMutual and Action Potential Venture Capital

Financing will support commercialization of a novel digital clinical management solution focused on immuno-oncology therapies Onc.AI, a medical technology company developing a novel digital clinical management solution focused on immuno-oncology, announced today it has closed a $25 million Series A financing co-led by MassMutual and Action Potential Venture Capital (a GSK venture fund). Also participating were Life Extension Ventures and all existing investors including Blue Venture Fund, Accomplice, Digitalis Ventures, and KdT Ventures. “Having first learned about Onc.AI through a leading precision-oncology expert, we are thrilled to partner with an exceptional team and help the company as they aim to serve medical oncologists and cancer patients broadly,” said David Diaz-Casariego, Portfolio Manager of Alternative Investments at MassMutual. New investor Action Potential Venture Capital invests in companies advancing the fields of bioelectronic medicines, and enabling technologies for precision medicine. “Onc.AI’s novel platform, which leverages radiomics and deep learning, has the potential to improve medical oncologist clinical decision-making and to meaningfully advance pharma immuno-oncology research and clinical trials,” said Juan-Pablo Mas, partner at Action Potential Venture Capital (APVC). “APVC is excited to support the team’s efforts in establishing a leadership position in this emerging category.” In conjunction with the financing, David Diaz-Casar...
Source: EMR and HIPAA - Category: Information Technology Authors: Tags: Genomics-Precision Medicine Health IT Company Healthcare IT Accomplice Action Potential Venture Capital Akshay Nanduri APVC Blue Venture Fund David Diaz-Casariego Digitalis Ventures Dr. Emir Sandhu Dr. Julie Hambleton GlaxoSmithKli Source Type: blogs